Related Articles
Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation
Guillain Barré Syndrome in a multiple myeloma patient after the first course of bortezomib therapy: A case report
Efferocytosis in multisystem diseases (Review)
Short‑course bortezomib‑based retreatment for patients with multiple myeloma who had received bortezomib‑thalidomide‑dexamethasone (VTD) as an initial therapy: A single‑center case series
Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells